NIPH Clinical Trials Search

UMIN ID: C000000090

Registered date:31/08/2005

The Japan Working Group for the Assessment That the Alpha-glucosidase-inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedPatients With Myocardial Infarction and IGT
Date of first enrollment2005/04/01
Target sample size1570
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)In the voglibose group, voglibose will be prescribed at 0.6mg three times daily. In control group, each participated doctor will instruct patients on a weight reduction or weight maintenance diet, and encouraged them to exercise regularly.


Primary Outcome1.Cardiovascular mortality 2.Hospitalization due to cardiovascular events
Secondary Outcome(1) All cause mortality (2) Hospitalization due to coronary artery disease (3) Progression of IGT to diabetes (4) Development or deterioration of either hypertension or hyperlipidemia (5) Deterioraion of renal function (6) Hospitalization due to cerebrovascular disease (7) Hospitalization due to heart failure

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum100years-old
GenderMale and Female
Include criteria
Exclude criteria1.Type I diabetes 2.History of coronary artery bypass graft 3.Severe liver and/or kidney dysfunction 4.History of allergic response to drugs 5.arteriosclerosis obliterans

Related Information


public contact
Name Masafumi Kitakaze
Address 5-7-1 Fujishirodai, Suita Osaka 565-8565, JAPAN Japan
Telephone 06-6836-5012
Affiliation Clinical Study Support Center Japan (CSSCJ) ABC office
scientific contact
Name Masafumi Kitakaze
Address 5-7-1 Fujishirodai, Suita City, Osaka Pref. 565-8565, Japan Japan
Telephone 06-6833-5012
Affiliation National Cardiovascular Center Cardiovascular Division